Parkinsonism & Related Disorders
Volume 16, Issue 3 , Pages 215-217 , March 2010

Working capacity and cervical dystonia

  • Kirsti K. Martikainen

      Affiliations

    • The Finnish Parkinson Association and Foundation, PO Box 905, FIN-20101 Turku, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 2 2740424; fax: +358 2 2740444.
    • ,
  • Tiina H. Luukkaala

      Affiliations

    • Pirkanmaa Hospital District, Science Center, Tampere, Finland
    • Tampere School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Reijo J. Marttila

      Affiliations

    • Department of Neurology, University of Turku, Turku, Finland

Received 18 March 2009 ,Revised 28 June 2009 ,Accepted 15 July 2009.

References 

  1. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247:787–792
  2. Erjanti HM, Marttila RJ, Rinne UK. The prevalence and incidence of cervical dystonia in south-western Finland. Mov Disord. 1996;11(Suppl. 1):215
  3. Skogseid IM, Rǿislien J, Claussen B, Kerty E. Long-term Botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord. 2005;20:1604–1609
  4. Ben-Shlomo Y, Camfield L, Warner T on behalf of the ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia?. J Neurol Neurosurg Psychiatry. 2002;72:608–614
  5. Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, et al. and the Austrian Botulinum Toxin and Dystonia Study Group The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249:842–846
  6. Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, et al. and the Austrian Botulinum Toxin and Dystonia Study Group Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry. 2004;75:749–753
  7. Statistical Yearbook of Finland 2005. Jyväskylä: Gummerus kirjapaino Oy; 2005;pp. 373–374
  8. Spliethoff-Kamminga NGA, Zimmerman AH, Springer MP, Roos RAC. Difference in quality of life and psychosocial well-being between Parkinson disease patient members and non-members of the Dutch Parkinson Disease Association. In:  Noëlle GA,  Spliethoff- Kamminga NGA editor. Psychosocial Problems in Parkinson's Disease. Leiden: Graphische Producties, Universitair Facilitair Bedrijf; 2004;p. 79–89
  9. Hilker R, Schischniasvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71:193–199
  10. Brefel-Courbon C, Simonetta-Moreau M, Moré C, Rascol O, Clanet M, Montastruc J-L, et al. A pharmacoeconomic evaluation of Botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol. 2000;23:203–207
  11. Jahanshahi M. Psychosocial factors and depression in torticollis. J Psychosom Res. 1991;35(4–5):493–507

☆ The review of this paper was entirely handled by an Associate Editor, Vincenzo Bonifati.

PII: S1353-8020(09)00195-3

doi: 10.1016/j.parkreldis.2009.07.006

Parkinsonism & Related Disorders
Volume 16, Issue 3 , Pages 215-217 , March 2010

Article Tools

* Image Usage & Resolution